A clinical review of studies on bisphosphonate therapy for pediatric osteoporosis has revealed that they increase BMD, but whether they also improve fracture rates or functions of daily life is unclear. Can the findings of this clinical review help inform clinicians whether, when and how to use these agents in children?
Access options
Subscribe to Journal
Get full journal access for 1 year
$59.00
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1
Bachrach, L. K. & Ward, L. M. Clinical review: bisphosphonate use in childhood osteoporosis. J. Clin. Endocrinol. Metab. 94, 400–409 (2009).
- 2
Letocha, A. D. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J. Bone Miner. Res. 20, 977–986 (2005).
- 3
Marini, J. C. Should children with osteogenesis imperfecta be treated with bisphosphonates? Nat. Clin. Pract. Endocrinol. Metab. 2, 14–15 (2006).
- 4
Rauch, F., Travers, R. & Glorieux, F. H. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J. Clin. Endocrinol. Metab. 91, 511–616 (2006).
- 5
Uveges, T. E. et al. Alendronate treatment of Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J. Bone Miner. Res. [doi:10.1359/jbmr.081238] (2008).
- 6
Li, J. S. et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297, 480–488 (2007).
- 7
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H. & Mumm, S. Bisphosphonate-induced osteopetrosis. N. Engl. J. Med. 349, 457–463 (2003).
- 8
Whyte, M. P. et al. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J. Bone Miner. Res. 23, 1698–1707 (2008).
- 9
Allen, M. R. & Burr, D. B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 22, 1759–1765 (2007).
- 10
Weinstein, R. S., Robertson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53–62 (2009).
Author information
Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Marini, J. Use of bisphosphonates in children—proceed with caution. Nat Rev Endocrinol 5, 241–243 (2009). https://doi.org/10.1038/nrendo.2009.58
Issue Date:
Further reading
-
Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta
BioMed Research International (2021)
-
Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice
Scientific Reports (2019)
-
Siglec-15-targeting therapy increases bone mass in rats without impairing skeletal growth
Bone (2018)
-
Challenges of Fracture Management for Adults With Osteogenesis Imperfecta
Orthopedics (2017)
-
Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta
Journal of Bone and Mineral Research (2016)
